Swissconsortium

Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy

Y Suzuki, Y Aono, M Kono, H Hasegawa… - …, 2021 - Wiley Online Library
Background and objective Recent research has highlighted the fundamental role of
sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor …
被引用次数：28 相关文章
Swissconsortium

Cause of Mortality and Sarcopenia in Patients with Idiopathic Pulmonary Fibrosis Receiving Anti-Fibrotic Therapy

Y Suzuki, Y Aono, M Kono, H Hasegawa… - …, 2021 - hama-med.repo.nii.ac.jp
Background and objective: Recent research has highlighted the fundamental role of
sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor …
Swissconsortium

Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy.

Y Suzuki, Y Aono, M Kono, H Hasegawa… - Respirology (Carlton …, 2020 - europepmc.org
Methods This study comprised two cohorts of patients with IPF receiving AFT, historical
cohort of IPF patients without AFT and controls. The cause of mortality was compared with a …
Swissconsortium

Cause of Mortality and Sarcopenia in Patients with Idiopathic Pulmonary Fibrosis Receiving Anti-Fibrotic Therapy

Y Suzuki, Y Aono, M Kono, H Hasegawa, K Yokomura… - Respirology, 2021 - cir.nii.ac.jp
抄録 Summary at GlanceSkeletal muscle wasting (sarcopenia) without obvious weight loss
is commonly found in patients with IPF receiving antifibrotic therapy. Most study patients died …
Swissconsortium

Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy

Y Suzuki, Y Aono, M Kono… - Respirology …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and objective Recent research has highlighted the fundamental role of
sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor …
Swissconsortium

Cause of Mortality and Sarcopenia in Patients with Idiopathic Pulmonary Fibrosis Receiving Anti-Fibrotic Therapy

Y Suzuki, Y Aono, M Kono, H Hasegawa… - …, 2021 - hama-med.repo.nii.ac.jp
Background and objective: Recent research has highlighted the fundamental role of
sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor …
Swissconsortium

[引用][C] Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy

Y Suzuki, Y Aono, M Kono, H Hasegawa, K Yokomura… - Respirology, 2020 - cir.nii.ac.jp
Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving
antifibrotic therapy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …